Cap-Dependent Translation Initiation Factor eIF4E

An Emerging Anticancer Drug Target

Yan Jia, Vitaly A Polunovsky, Peter B Bitterman, Carston R Wagner

Research output: Contribution to journalReview article

61 Citations (Scopus)

Abstract

Cancer cells tend to be more highly dependent on cap-dependent translation than normal tissues. Thus, proteins involved in the initiation of cap-dependent translation have emerged as potential anti-cancer drug targets. Cap-dependent translation is initiated by the binding of the factor eIF4E to the cap domain of mRNA. Detailed x-ray crystal and NMR structures are available for eIF4E in association with cap-analogs, as well as domains of other initiation factors. This review will summarize efforts to design potential antagonist of eIF4E that could be used as new pharmacological tools and anti-cancer agents and. Insights drawn from these studies should aid in the design of future inhibitors of eIF4E dependent translation initiation.

Original languageEnglish (US)
Pages (from-to)786-814
Number of pages29
JournalMedicinal Research Reviews
Volume32
Issue number4
DOIs
StatePublished - Jul 1 2012

Fingerprint

Peptide Initiation Factors
Pharmaceutical Preparations
Neoplasms
X-Rays
Pharmacology
Messenger RNA
Proteins

Keywords

  • Anticancer
  • EIF4E
  • Translation

Cite this

Cap-Dependent Translation Initiation Factor eIF4E : An Emerging Anticancer Drug Target. / Jia, Yan; Polunovsky, Vitaly A; Bitterman, Peter B; Wagner, Carston R.

In: Medicinal Research Reviews, Vol. 32, No. 4, 01.07.2012, p. 786-814.

Research output: Contribution to journalReview article

@article{24d8a0e7269343f6bd8811679ba98856,
title = "Cap-Dependent Translation Initiation Factor eIF4E: An Emerging Anticancer Drug Target",
abstract = "Cancer cells tend to be more highly dependent on cap-dependent translation than normal tissues. Thus, proteins involved in the initiation of cap-dependent translation have emerged as potential anti-cancer drug targets. Cap-dependent translation is initiated by the binding of the factor eIF4E to the cap domain of mRNA. Detailed x-ray crystal and NMR structures are available for eIF4E in association with cap-analogs, as well as domains of other initiation factors. This review will summarize efforts to design potential antagonist of eIF4E that could be used as new pharmacological tools and anti-cancer agents and. Insights drawn from these studies should aid in the design of future inhibitors of eIF4E dependent translation initiation.",
keywords = "Anticancer, EIF4E, Translation",
author = "Yan Jia and Polunovsky, {Vitaly A} and Bitterman, {Peter B} and Wagner, {Carston R}",
year = "2012",
month = "7",
day = "1",
doi = "10.1002/med.21260",
language = "English (US)",
volume = "32",
pages = "786--814",
journal = "Medicinal Research Reviews",
issn = "0198-6325",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Cap-Dependent Translation Initiation Factor eIF4E

T2 - An Emerging Anticancer Drug Target

AU - Jia, Yan

AU - Polunovsky, Vitaly A

AU - Bitterman, Peter B

AU - Wagner, Carston R

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Cancer cells tend to be more highly dependent on cap-dependent translation than normal tissues. Thus, proteins involved in the initiation of cap-dependent translation have emerged as potential anti-cancer drug targets. Cap-dependent translation is initiated by the binding of the factor eIF4E to the cap domain of mRNA. Detailed x-ray crystal and NMR structures are available for eIF4E in association with cap-analogs, as well as domains of other initiation factors. This review will summarize efforts to design potential antagonist of eIF4E that could be used as new pharmacological tools and anti-cancer agents and. Insights drawn from these studies should aid in the design of future inhibitors of eIF4E dependent translation initiation.

AB - Cancer cells tend to be more highly dependent on cap-dependent translation than normal tissues. Thus, proteins involved in the initiation of cap-dependent translation have emerged as potential anti-cancer drug targets. Cap-dependent translation is initiated by the binding of the factor eIF4E to the cap domain of mRNA. Detailed x-ray crystal and NMR structures are available for eIF4E in association with cap-analogs, as well as domains of other initiation factors. This review will summarize efforts to design potential antagonist of eIF4E that could be used as new pharmacological tools and anti-cancer agents and. Insights drawn from these studies should aid in the design of future inhibitors of eIF4E dependent translation initiation.

KW - Anticancer

KW - EIF4E

KW - Translation

UR - http://www.scopus.com/inward/record.url?scp=84863838830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863838830&partnerID=8YFLogxK

U2 - 10.1002/med.21260

DO - 10.1002/med.21260

M3 - Review article

VL - 32

SP - 786

EP - 814

JO - Medicinal Research Reviews

JF - Medicinal Research Reviews

SN - 0198-6325

IS - 4

ER -